Lipoprotein(a) and Benefit of PCSK9 Inhibition in Emergency Complex Higher-risk and Indicated Patients

被引：0
|
作者：
Zhi-li Jin
Tao He
Li Peng
Xiao-yan Wu
Di Fan
Ming Chen
Yong-zhen Fan
Yuan-lin Guo
Zhi-bing Lu
Hai-rong Wang
机构：
[1] Zhongnan Hospital of Wuhan University,Department of Cardiovascular Medicine
[2] Wuhan University,Institute of Myocardial Injury and Repair
[3] Chinese Academy of Medical Sciences & Peking Union Medical College,Cardio
来源：
Current Medical Science | 2023年 / 43卷
关键词：
PCSK9 inhibitor; complex higher-risk and indicated patients; lipoprotein(a) level; low-density lipoprotein cholesterol level; 2-year cardiovascular event rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1206 / 1212
页数：6
相关论文
共 50 条
  • [31] Atherosclerosis PCSK9 inhibition reduces cardiovascular events in high-risk patients
    Huynh, Karina
    NATURE REVIEWS CARDIOLOGY, 2017, 14 (05) : 2 - 2
  • [32] PCSK9 inhibition in patients with heart transplantation: A case series
    Sandesara, Pratik B.
    Dhindsa, Devinder
    Hirsh, Benjamin
    Jokhadar, Maan
    Cole, Robert T.
    Sperling, Laurence S.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2019, 13 (05) : 721 - 724
  • [33] Complex, Higher-Risk, and Indicated PCI (CHIP) Fellowship Putting Training Into Practice
    Riley, Robert F.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 75 (08) : 980 - 983
  • [34] Reduction of Low-Density Lipoprotein Cholesterol by Monoclonal Antibody Inhibition of PCSK9
    Stein, Evan A.
    Raal, Frederick
    ANNUAL REVIEW OF MEDICINE, VOL 65, 2014, 65 : 417 - 431
  • [35] Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
    Pradhan, Aruna D.
    Aday, Aaron W.
    Rose, Lynda M.
    Ridker, Paul M.
    CIRCULATION, 2018, 138 (02) : 141 - 149
  • [36] DYNAMICS OF PLASMA LEVELS OF LIPOPROTEIN(A), PCSK9, AND THEIR COMPLEX AFTER A SINGLE INJECTION OF EVOLOCUMAB
    Afanasieva, O.
    Ezhov, M.
    Egiazaryan, M.
    Klesareva, E.
    Utkina, E.
    Pokrovsky, S.
    ATHEROSCLEROSIS, 2019, 287 : E198 - E198
  • [37] PCSK9 inhibition for patients with and without prior coronary revascularization: Potential additional benefit of a novel therapeutic agent
    Navarese, Eliano P.
    Raggi, Paolo
    ATHEROSCLEROSIS, 2018, 277 : 177 - 178
  • [38] PLASMA PCSK9 LEVELS AND LIPOPROTEIN DISTRIBUTION ARE PRESERVED IN PATIENTS WITH SEVERE HYPOALPHALIPOPROTEINEMIA
    Ruscica, Massimiliano
    Simonelli, Sara
    Botta, Margherita
    Ossoli, Alice
    Magni, Paolo
    Corsini, Alberto
    Arca, Marcello
    Pisciotta, Livia
    Veglia, Fabrizio
    Franceschini, Guido
    Ferri, Nicola
    Calabresi, Laura
    ATHEROSCLEROSIS, 2017, 263 : E91 - E91
  • [39] Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
    Li, Tingting
    Zhang, Yingyi
    Cong, Hongliang
    BMC CARDIOVASCULAR DISORDERS, 2021, 21 (01)
  • [40] Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes
    Tingting Li
    Yingyi Zhang
    Hongliang Cong
    BMC Cardiovascular Disorders, 21
12345